About VaxSyna
VaxSyna is a Healthcare company based in Boston (United States) founded in 2020. Developer of vaccine and antibody therapeutics. VaxSyna offers products and services including Vaccines and Therapeutics Platform. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified. Its competitors include BeiGene, Vir Biotechnology and Vaxcyte; 3 of its 3 listed competitors have raised funding.
Company details
VaxSyna was founded in 2020 and is headquartered in Boston, United States. Operations are centered in the biotechnology sector, where plant-based vaccines and antibody therapeutics are developed to address pathogenic diseases and cancer. Focus is placed on innovative production methods derived from plant systems, supporting research and development efforts in immunology and oncology applications.
- Headquarters Boston, United States
- SectorsHealthcare
- Email••••••••
- Website vaxsyna.com
- Social LinkedIn
- Latest Funding Round$437.2K (USD), Grant
Apr 2022
- Investors
Products & Services of VaxSyna
VaxSyna offers a comprehensive portfolio of products and services, including Vaccines and Therapeutics Platform.
Develops platforms for rapid creation of vaccines and therapeutics against infectious diseases.
Funding Insights of VaxSyna
- Total Rounds 1
- Last Round Grant — $437,203
- First Round $437,203
(Apr 2022)
- Investors Count 1
All 1 funding rounds of VaxSyna with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $437,203 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in VaxSyna
VaxSyna has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for VaxSyna
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of VaxSyna
2 dated milestones of VaxSyna across 2 years, from founding to its latest funding, stage changes and deals.
- Founded VaxSyna is founded.
- Funding First funding round of $437K.
Competitors of VaxSyna
VaxSyna has 3 listed competitors in our database, 3 of them funded. They include BeiGene, Vir Biotechnology and Vaxcyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. |
Detailed competitors of VaxSyna
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as VaxSyna (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VaxSyna
VaxSyna was founded in 2020 and raised its 1st funding round 2 years after it was founded.
VaxSyna is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
VaxSyna was founded in 2020 and is headquartered in Boston, United States. Operations are centered in the biotechnology sector, where plant-based vaccines and antibody therapeutics are developed to address pathogenic diseases and cancer. Focus is placed on innovative production methods derived from plant systems, supporting research and development efforts in immunology and oncology applications.
VaxSyna's top competitors include BeiGene, Vaxcyte and Vir Biotechnology.
VaxSyna offers Vaccines and Therapeutics Platform.
VaxSyna has 1 investor. Key investors include HHS.